LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund lessened its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 0.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,685 shares of the medical instruments supplier’s stock after selling 208 shares during the quarter. New York State Common Retirement Fund’s holdings in LeMaitre Vascular were worth $1,515,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Exchange Traded Concepts LLC raised its position in LeMaitre Vascular by 0.8% during the 4th quarter. Exchange Traded Concepts LLC now owns 23,656 shares of the medical instruments supplier’s stock worth $1,343,000 after buying an additional 187 shares during the last quarter. Riverwater Partners LLC boosted its holdings in LeMaitre Vascular by 2.5% in the 4th quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock valued at $466,000 after purchasing an additional 198 shares in the last quarter. Swiss National Bank increased its position in LeMaitre Vascular by 1.2% during the 3rd quarter. Swiss National Bank now owns 43,900 shares of the medical instruments supplier’s stock worth $2,392,000 after purchasing an additional 500 shares during the period. Victory Capital Management Inc. increased its position in LeMaitre Vascular by 0.7% during the 3rd quarter. Victory Capital Management Inc. now owns 76,915 shares of the medical instruments supplier’s stock worth $4,190,000 after purchasing an additional 557 shares during the period. Finally, Values First Advisors Inc. raised its stake in shares of LeMaitre Vascular by 1.9% during the 4th quarter. Values First Advisors Inc. now owns 33,617 shares of the medical instruments supplier’s stock worth $1,908,000 after buying an additional 626 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director Lawrence J. Jasinski sold 5,110 shares of LeMaitre Vascular stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total value of $344,925.00. Following the transaction, the director now directly owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 8,000 shares of the stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $75.30, for a total value of $602,400.00. Following the completion of the sale, the chief executive officer now owns 2,079,128 shares of the company’s stock, valued at $156,558,338.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lawrence J. Jasinski sold 5,110 shares of the business’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the transaction, the director now directly owns 5,309 shares in the company, valued at $358,357.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 195,967 shares of company stock valued at $14,072,324. Company insiders own 10.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Barrington Research upped their price objective on LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. KeyCorp started coverage on shares of LeMaitre Vascular in a report on Tuesday, February 6th. They set a “sector weight” rating on the stock. Stifel Nicolaus raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and increased their target price for the company from $59.00 to $75.00 in a report on Friday, April 26th. JMP Securities boosted their price target on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a research note on Friday, May 3rd. Finally, StockNews.com upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $73.83.

LeMaitre Vascular Price Performance

LMAT stock opened at $76.00 on Friday. The company’s 50 day simple moving average is $66.67 and its 200-day simple moving average is $59.46. LeMaitre Vascular, Inc. has a 12 month low of $44.27 and a 12 month high of $76.24. The firm has a market capitalization of $1.71 billion, a PE ratio of 50.33, a P/E/G ratio of 2.99 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The firm had revenue of $53.48 million for the quarter, compared to analyst estimates of $51.50 million. During the same quarter in the prior year, the company earned $0.27 EPS. LeMaitre Vascular’s revenue was up 13.6% on a year-over-year basis. As a group, sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th will be paid a $0.16 dividend. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $0.64 annualized dividend and a yield of 0.84%. LeMaitre Vascular’s payout ratio is currently 42.38%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.